je.st
news
Tag: drugs
Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs
2015-11-30 13:55:15| Biotech - Topix.net
A Dallas Buyers Club- style operation that helps hepatitis C patients get lifesaving drugs at knockdown prices plans to go a step further for World Aids Day on Tuesday - free drugs for those who can least afford them. Nearly a quarter of a million Australians carry hepatitis C, a "viral time bomb" that kills half a million people worldwide each year, according to the World Health Organisation.
AMA Calls For Ban On Direct To Consumer Advertising Of Prescription Drugs And Medical Devices
2015-11-19 08:31:44| drugdiscoveryonline Home Page
Responding to the billions of advertising dollars being spent to promote prescription products, physicians at the Interim Meeting of the American Medical Association (AMA) recently adopted new policy aimed at driving solutions to make prescription drugs more affordable.
Tags: direct
advertising
medical
consumer
Top healthcare stock fund focuses on costs, orphan drugs in 2016
2015-11-18 01:43:18| Biotech - Topix.net
Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. Fraunces, who co-manages the $134 million fund, said he has been increasing his short positions, or bets that shares will decline, on companies that face increased price pressure for high-priced drugs.
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the companys Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
GlaxoSmithKline plans to seek approval for up to 20 new drugs by 2020, start studies on others
2015-11-04 04:50:02| Biotech - Topix.net
GlaxoSmithKline could seek regulatory approval for up to 20 new medicines before 2020 and some could hit the market by then, enabling it to boost revenue rather than just compensate for declining sales of its older drugs. The British drugmaker said it could start late-stage patient testing in the next two years on about 20 new drugs or new uses for existing ones.
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »